Skip to main content

Published locations for FDA panel backs evolocumab for lowering LDL in high-risk patients

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. FDA panel backs evolocumab for lowering LDL in high-risk patients

User login

  • Reset your password
  • /content/fda-panel-backs-evolocumab-lowering-ldl-high-risk-patients
  • /familypracticenews/article/100363/lipid-disorders/fda-panel-backs-evolocumab-lowering-ldl-high-risk
  • /internalmedicinenews/article/100363/lipid-disorders/fda-panel-backs-evolocumab-lowering-ldl-high
  • /node/155702/article/100363/lipid-disorders/fda-panel-backs-evolocumab-lowering-ldl-high-risk
  • /vascularspecialistonline/article/100363/lipid-disorders/fda-panel-backs-evolocumab-lowering-ldl-high
  • /clinicalendocrinologynews/article/100363/lipid-disorders/fda-panel-backs-evolocumab-lowering-ldl
  • /ecardiologynews/article/100363/lipid-disorders/fda-panel-backs-evolocumab-lowering-ldl-high-risk
  • /cardiology/article/100363/lipid-disorders/fda-panel-backs-evolocumab-lowering-ldl-high-risk-patients
  • /endocrinology/article/100363/lipid-disorders/fda-panel-backs-evolocumab-lowering-ldl-high-risk
  • /internalmedicine/article/100363/lipid-disorders/fda-panel-backs-evolocumab-lowering-ldl-high-risk
  • /familymedicine/article/100363/lipid-disorders/fda-panel-backs-evolocumab-lowering-ldl-high-risk